 2. Cohort B: This adoptive cell transfer ACT step will in additional 5 patients be followed by a vaccination with autologous, in vitro-generated, dendritic cells DC, loaded with autologous tumor lysate and a synthetically produced peptide derived from the tumor associated antigen NY-ESO 1. 